Antidiabetic drugs and kidney disease - Recommendations of the Swiss Society for Endocrinology and Diabetology.

Fiche du document

Auteurs
Date

2012

Types de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.4414/smw.2012.13629

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/22987488

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1424-3997

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0B982F37FE276

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer

Sujets proches En

illness

Citer ce document

A. Zanchi et al., « Antidiabetic drugs and kidney disease - Recommendations of the Swiss Society for Endocrinology and Diabetology. », Serveur académique Lausannois, ID : 10.4414/smw.2012.13629

Métriques

Partage / Export

Résumé 0

Patients with diabetes are at risk of early renal function decline. Therefore, kidney function needs monitoring at least once per year. Once the glomerular filtration rate (GFR) is less than 60 ml/min, the pharmacokinetics of antidiabetic drugs may be altered. Sulfonylurea and glinide therapies are associated with a risk of hypoglycaemia which is increased in the presence of renal impairment. Most sulfonylureas must be discontinued once GFR is

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en